Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax in chronic lymphocytic leukemia with 17p deletion
2012-004027-20Phase 2Unknown
- Sponsor
- AbbVie Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AbbVie Inc. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-004027-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004027-20.